Search Results

Bio-Thera Solutions Inc., a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for Avzivi®, a biosimilar monoclonal antibody referencing AVASTIN®.

Bio-Thera Solutions announced today a new licensing agreement for two biosimilars under which SteinCares will have exclusive rights to distribute and market Bio-Thera’s pharmaceuticals in Brazil and the rest of the region.

Bio-Thera Solutions (688177:SH) and global specialty, generic and consumer healthcare medicines company STADA Arzneimittel AG have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® (golimumab).

Bio-Thera Solutions Inc. will present a poster at the 2024 ASCO Annual Meeting entitled “Phase 1 study of BAT8006, a folate receptor α antibody drug conjugate with strong bystander effect, in subjects with advanced solid tumors,” that highlights clinical data for the potential best-in-class efficacy and safety of BAT8006 as a potential treatment for ovarian cancer patients and other patients with tumors that express Folate Receptor-alpha.

Bio-Thera Solutions today announced receiving IND clearance from the US FDA for a phase II Study for BAT8006, an innovative Antibody Drug Conjugate (ADC) targeting Folate Receptor α (FRα).

Bio-Thera Solutions, Ltd (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, today announced that the United States Food and Drug Administration (FDA) has approved Avzivi® (bevacizumab-tnjn), a biosimilar referencing Avastin®.

Bio-Thera Solutions, Ltd., a commercial-stage biopharmaceutical company developing a pipeline of biosimilars and innovative assets, announced results from the Phase 3 study of BAT2206, a proposed biosimilar referencing Stelara®.